Valentine Frydman1, Ugo Pinar1, Maher Abdessater1, William Akakpo2, Pietro Grande2, Marie Audouin3, Pierre Mozer2, Emmanuel Chartier-Kastler2, Thomas Seisen1, Morgan Roupret4. 1. Department of Urology, Sorbonne Université, GRC n 5, Predictive Onco-Urology, APHP, Hôpital Pitié-Salpêtrière, F-75013, Paris, France. 2. Department of Urology, Sorbonne Université, APHP, Hôpitaux universitaires Pitié-Salpêtrière-Charles Foix, F-75013, Paris, France. 3. Department of Urology, Sorbonne Université, APHP, Hôpital Tenon, F-75013, Paris, France. 4. Department of Urology, Sorbonne Université, GRC n 5, Predictive Onco-Urology, APHP, Hôpital Pitié-Salpêtrière, F-75013, Paris, France. morgan.roupret@aphp.fr.
Abstract
BACKGROUND: Penile prothesis (PP) is the gold-standard treatment of drug-refractory erectile dysfunction (ED). While postoperative outcomes have been widely described in the literature, there are few data about patient satisfaction and intraoperative events. We aimed to assess long-term patient satisfaction and perioperative outcomes after PP implantation in a single-centre cohort of unselected patients using validated scales. RESULTS: A total of 130 patients received a PP (median age: 62.5 years [IQR: 58-69]; median International Index of Erectile Function (IEEF-5) score: 6 [IQR: 5-7]). Median follow-up was 6.3 years [IQR: 4-9.4]. Thirty-two (24.6%) patients underwent surgical revision, of which 20 were PP removals (15.4%). Global PP survival rate was 84.6% and previous PP placement was a risk factor for PP removal (p = 0.02). There were six (4.6%) non-life-threatening intraoperative events including two which resulted in non-placement of a PP (1.5%). EAUiaic grade was 0 for 124 procedures (95.4%), 1 for four procedures (3.1%) and 2 for two procedures (1.5%). Of patients who still had their PP at the end of the study, 91 (80.5%) expressed satisfaction. CONCLUSIONS: PP implantation is a last-resort treatment for ED with a satisfactory outcome. PPs are well accepted by patients.
BACKGROUND: Penile prothesis (PP) is the gold-standard treatment of drug-refractory erectile dysfunction (ED). While postoperative outcomes have been widely described in the literature, there are few data about patient satisfaction and intraoperative events. We aimed to assess long-term patient satisfaction and perioperative outcomes after PP implantation in a single-centre cohort of unselected patients using validated scales. RESULTS: A total of 130 patients received a PP (median age: 62.5 years [IQR: 58-69]; median International Index of Erectile Function (IEEF-5) score: 6 [IQR: 5-7]). Median follow-up was 6.3 years [IQR: 4-9.4]. Thirty-two (24.6%) patients underwent surgical revision, of which 20 were PP removals (15.4%). Global PP survival rate was 84.6% and previous PP placement was a risk factor for PP removal (p = 0.02). There were six (4.6%) non-life-threatening intraoperative events including two which resulted in non-placement of a PP (1.5%). EAUiaic grade was 0 for 124 procedures (95.4%), 1 for four procedures (3.1%) and 2 for two procedures (1.5%). Of patients who still had their PP at the end of the study, 91 (80.5%) expressed satisfaction. CONCLUSIONS: PP implantation is a last-resort treatment for ED with a satisfactory outcome. PPs are well accepted by patients.
Authors: Pietro Grande; Gabriele Antonini; Cristiano Cristini; Ettore De Berardinis; Antonio Gatto; Giovanni Di Lascio; Andrea Lemma; Giuseppe Gentile; Giovanni Battista Di Pierro Journal: World J Urol Date: 2018-02-28 Impact factor: 4.226
Authors: Gerard D Henry; Steven K Wilson; John R Delk; Culley C Carson; Ari Silverstein; Mario A Cleves; Craig F Donatucci Journal: J Urol Date: 2004-07 Impact factor: 7.450
Authors: Emilie Dardenne; Quentin Manach; Pietro Grande; Riccardo Campi; Florie Gomez; Benjamin Granger; Vincent Misrai; Marc-Olivier Bitker; Pierre Mozer; Morgan Roupret Journal: Can J Urol Date: 2019-12 Impact factor: 1.344